The DOI matches its Crossref record; 14 of the 14 references it cites were found in a registry or an index.
Plasma Testosterone and Sexual Function in Men Receiving Buprenorphine Maintenance for Opioid Dependence
Abstract
High-dose methadone is well known to cause testosterone deficiency and sexual dysfunction in opioid-dependent men. Buprenorphine is a new drug for the pharmacotherapy of opioid dependence. Its influence on the gonadal axis has not been investigated to date. We therefore assayed testosterone, free testosterone, estradiol, SHBG, LH, FSH, and prolactin in 17 men treated with buprenorphine. Thirty-seven men treated with high-dose methadone and 51 healthy blood donors served as controls. Sexual function and depression were assessed using a self-rating sexual function questionnaire and the Beck Depression Inventory. Patients treated with buprenorphine had a significantly higher testosterone level [5.1 +/- 1.2 ng/ml (17.7 +/- 4.2 nmol/liter) vs. 2.8 +/- 1.2 ng/ml (9.7 +/- 4.2 nmol/liter); P < 0.0001] and a significantly lower frequency of sexual dysfunction (P < 0.0001) compared with patients treated with methadone. The testosterone level of buprenorphine-treated patients did not differ from that of healthy controls. In conclusion, we demonstrated for the first time that buprenorphine, in contrast with high-dose methadone, seems not to suppress plasma testosterone in heroin-addicted men. To this effect, buprenorphine was less frequently related to sexual side effects. Buprenorphine might therefore be favored in the treatment of opioid dependence to prevent patients from the clinical consequences of methadone-induced hypogonadism.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Buprenorphine, a partial opioid receptor agonist, is associated with milder effects on the hypothalamic-pituitary-gonadal system (91,92).”
From Exogenous Opioids and the Human Endocrine System: An Endocrine Society Scientific Statement (2024) · cites this paper as [91]
In the citing paper
“In patients on methadone or buprenorphine maintenance treatment, PRL has been found to be reduced, similar, or higher when compared with controls (91,150,151).”
From Exogenous Opioids and the Human Endocrine System: An Endocrine Society Scientific Statement (2024) · cites this paper as [91]
Citations
Cites
Psychometric properties of the Beck Depression Inventory: Twenty-five years of evaluation
Beck, A. T., Steer, R. A., & Carbin, M. G. (1988) · Clinical Psychology Review · doi:10.1016/0272-7358(88)90050-5 · Cited by 11,696
A Comparison of Levomethadyl Acetate, Buprenorphine, and Methadone for Opioid Dependence
Johnson, R. E., Chutuape, M. A., Strain, E. C., Walsh, S. L., Stitzer, M. L., & Bigelow, G. E. (2000) · New England Journal of Medicine · doi:10.1056/nejm200011023431802 · Cited by 623
A Controlled Trial of Buprenorphine Treatment for Opioid Dependence
Johnson, R. E. (1992) · JAMA: The Journal of the American Medical Association · doi:10.1001/jama.1992.03480200058024 · Cited by 572
Function of the Male Sex Organs in Heroin and Methadone Users
Cicero, T. J., Bell, R. D., Wiest, W. G., Allison, J. H., Polakoski, K., & Robins, E. (1975) · New England Journal of Medicine · doi:10.1056/nejm197504242921703 · Cited by 246
Buprenorphine: how to use it right
JOHNSON, R. (2003) · Drug and Alcohol Dependence · doi:10.1016/s0376-8716(03)00060-7 · Cited by 241
The clinical pharmacology of buprenorphine: extrapolating from the laboratory to the clinic
WALSH, S. (2003) · Drug and Alcohol Dependence · doi:10.1016/s0376-8716(03)00056-5 · Cited by 219
Plasma testosterone levels in heroin addiction and during methadone maintenance.
Mendelson, J., Mendelson, J., & Patch, V. (1975) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1016/s0022-3565(25)30047-9 · Cited by 161
Decreased serum testosterone concentration in male heroin and methadone addicts
Azizi, F., Vagenakis, A. G., Longcope, C., Ingbar, S. H., & Braverman, L. E. (1973) · Steroids · doi:10.1016/0039-128x(73)90002-0 · Cited by 130
Clinical efficacy of buprenorphine: comparisons to methadone and placebo
LING, W. (2003) · Drug and Alcohol Dependence · doi:10.1016/s0376-8716(03)00059-0 · Cited by 121
Opioid-induced suppression of rat testicular function.
Adams, M. L., Sewing, B. N., Forman, J. B., Meyer, E. R., & Cicero, T. J. (1993) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1016/s0022-3565(25)38343-6 · Cited by 87
Cited by
Opioid Complications and Side Effects
Benyamin, R. (2008) · Pain Physician · doi:10.36076/ppj.2008/11/s105 · Cited by 2,245
Bhasin, S., Cunningham, G. R., Hayes, F. J., Matsumoto, A. M., Snyder, P. J., Swerdloff, R. S., & Montori, V. M. (2010) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2009-2354 · Cited by 1,954
“The suppression of testosterone is particularly profound in men on methadone maintenance therapy because of its long duration of action; buprenorphine suppresses plasma testosterone to a lesser extent than methadone (24).”
BackgroundBhasin, S., Cunningham, G. R., Hayes, F. J., Matsumoto, A. M., Snyder, P. J., Swerdloff, R. S., & Montori, V. M. (2006) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2005-2847 · Cited by 965
The effects of opioids and opioid analogs on animal and human endocrine systems
Vuong, C., Van Uum, S. H. M., O'Dell, L. E., Lutfy, K., & Friedman, T. C. (2010) · Endocrine Reviews · doi:10.1210/er.2009-0009 · Cited by 564
Pain and Stress in a Systems Perspective: Reciprocal Neural, Endocrine, and Immune Interactions
Chapman, C. R., Tuckett, R. P., & Song, C. W. (2008) · The Journal of Pain · doi:10.1016/j.jpain.2007.09.006 · Cited by 541
Basaria, S. (2014) · The Lancet · doi:10.1016/s0140-6736(13)61126-5 · Cited by 328
Sex differences in the neural mechanisms mediating addiction: a new synthesis and hypothesis
Becker, J. B., Perry, A. N., & Westenbroek, C. (2012) · Biology of Sex Differences · doi:10.1186/2042-6410-3-14 · Cited by 317
“drawal or while on methadone maintenance [107,108].”
The impact of opioids on the endocrine system
Katz, N., & Mazer, N. A. (2009) · The Clinical Journal of Pain · doi:10.1097/ajp.0b013e3181850df6 · Cited by 307
“Tramadol and buprenorphine may not produce as much opioid hypogonadism as other compounds because they are not pure m agonists and have other properties: tramadol inhibits monoamine reuptake and buprenorphine is a partial m agonist with potential k antagonist features.(21)”
BackgroundCurrent Knowledge of Buprenorphine and Its Unique Pharmacological Profile
Pergolizzi, J., Aloisi, A. M., Dahan, A., Filitz, J., Langford, R., Likar, R., Mercadante, S., Morlion, B., Raffa, R. B., Sabatowski, R., et al. (2010) · Pain Practice · doi:10.1111/j.1533-2500.2010.00378.x · Cited by 284
“Clinicians using this opioid to rescue addicts already acknowledge these characteristics.(75) Most of the available clinical and experimental data in humans are obtained from male patients treated with morphine.”
BackgroundThe insults of illicit drug use on male fertility
Fronczak, C. M., Kim, E. D., & Barqawi, A. B. (2012) · Journal of Andrology · doi:10.2164/jandrol.110.011874 · Cited by 217
Buprenorphine – an attractive opioid with underutilized potential in treatment of chronic pain
Pillarisetti, S., & Khanna, I. (2015) · Journal of Pain Research · doi:10.2147/jpr.s85951 · Cited by 195
Chronic Pain in Canada: Have We Improved Our Management of Chronic Noncancer Pain?
Boulanger, A., Clark, A. J., Squire, P., Cui, E., & Horbay, G. (2007) · Pain Research and Management · doi:10.1155/2007/762180 · Cited by 187
“Recent reports of hypogonadism associated with long-term treatment with oral opioids in male cancer survivors (25) and with long-term methadone treatment of heroin addicts (26), but not with buprenorphine (27), may be significant and warrant further study.”
BackgroundTwelve Reasons for Considering Buprenorphine as a Frontline Analgesic in the Management of Pain
Davis, M. P. (2012) · The Journal of Supportive Oncology · doi:10.1016/j.suponc.2012.05.002 · Cited by 179
Erectile Dysfunction in Men Receiving Methadone and Buprenorphine Maintenance Treatment
Hallinan, R., Byrne, A., Agho, K., McMahon, C., Tynan, P., & Attia, J. (2008) · The Journal of Sexual Medicine · doi:10.1111/j.1743-6109.2007.00702.x · Cited by 166
The Effect of Opioid Therapy on Endocrine Function
Brennan, M. J. (2013) · The American Journal of Medicine · doi:10.1016/j.amjmed.2012.12.001 · Cited by 166
Buprenorphine/Naloxone: A Review of its Use in the Treatment of Opioid Dependence
Orman, J. S., & Keating, G. M. (2009) · Drugs · doi:10.2165/00003495-200969050-00006 · Cited by 160
“0001) lower incidence of impaired libido (23% vs 83%) and impaired potency (12% vs 72%) than those receiving high-dose methadone.([25]) In another study (n = 103), mean testosterone levels (18.”
Drug-induced gynecomastia: an evidence-based review
Deepinder, F., & Braunstein, G. D. (2012) · Expert Opinion on Drug Safety · doi:10.1517/14740338.2012.712109 · Cited by 151
“Methadone-induced suppression of testosterone levels is likely mediated by the inhibition of HPG axis as well as the direct reduction at the testicular level [95].”
BackgroundMale Hypogonadism in Systemic Disease
Kalyani, R. R., Gavini, S., & Dobs, A. S. (2007) · Endocrinology and Metabolism Clinics of North America · doi:10.1016/j.ecl.2007.03.014 · Cited by 149
Erectile Dysfunction in Patients with Hyper- and Hypothyroidism: How Common and Should We Treat?
Krassas, G. E., Tziomalos, K., Papadopoulou, F. G., Pontikides, N., & Perros, P. (2008) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2007-2259 · Cited by 141
Sexual Dysfunction in Patients with Alcohol and Opioid Dependence
Grover, S., Mattoo, S. K., Pendharkar, S. S., & Kandappan, V. (2014) · Indian Journal of Psychological Medicine · doi:10.4103/0253-7176.140699 · Cited by 140
“%) of those experiencing similar difficulties on methadone Persons with altered sexual function while on the street heroin represent a high-risk group for developing inadequate sexual function upon initiation of methadone maintenance Spring et al.[36] 25 men on MMT Derogatis sexual functioning inventory SD was more in…”
ResultInfluentialOpioids and their endocrine effects: a systematic review and meta-analysis
de Vries, F., Bruin, M., Lobatto, D. J., Dekkers, O. M., Schoones, J. W., van Furth, W. R., Pereira, A. M., Karavitaki, N., Biermasz, N. R., & Zamanipoor Najafabadi, A. H. (2020) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/clinem/dgz022 · Cited by 139
Understanding buprenorphine for use in chronic pain: expert opinion
Webster, L., Gudin, J., Raffa, R. B., Kuchera, J., Rauck, R., Fudin, J., Adler, J., & Mallick-Searle, T. (2020) · Pain Medicine · doi:10.1093/pm/pnz356 · Cited by 130
Hypogonadism in men receiving methadone and buprenorphine maintenance treatment
Hallinan, R., Byrne, A., Agho, K., McMahon, C. G., Tynan, P., & Attia, J. (2007) · International Journal of Andrology · doi:10.1111/j.1365-2605.2007.00824.x · Cited by 128
Ahmed, M. A., & Kurkar, A. (2014) · Clinical and Experimental Pharmacology and Physiology · doi:10.1111/1440-1681.12213 · Cited by 124
Testosterone suppression in opioid users: A systematic review and meta-analysis
Bawor, M., Bami, H., Dennis, B. B., Plater, C., Worster, A., Varenbut, M., Daiter, J., Marsh, D. C., Steiner, M., Anglin, R., et al. (2015) · Drug and Alcohol Dependence · doi:10.1016/j.drugalcdep.2015.01.038 · Cited by 123
HIV Risk Reduction With Buprenorphine–Naloxone or Methadone: Findings From a Randomized Trial
WOODY, G. E., Bruce, R. D., Korthuis, P. T., Chhatre, S., Poole, S. A., Hillhouse, M. P., Jacobs, P., Sorensen, J. L., Saxon, A. J., Metzger, D. S., et al. (2014) · JAIDS Journal of Acquired Immune Deficiency Syndromes · doi:10.1097/qai.0000000000000165 · Cited by 115
Oral opioids for chronic non-cancer pain: higher prevalence of hypogonadism in men than in women
Fraser, L.-A., Morrison, D., Morley-Forster, P., Paul, T., Tokmakejian, S., Larry Nicholson, R., Bureau, Y., Friedman, T., & Uum, S. H. M. V. (2008) · Experimental and Clinical Endocrinology & Diabetes · doi:10.1055/s-2008-1076715 · Cited by 112
“Recently, Bliessener et al. (Bliesener et al., 2005) reported that treatment with buprenorphine, a partial opioid receptor agonist, did not decrease testosterone levels, this in contrast to the hypogonadal effect of high dose methadone.”
BackgroundStrasser, F., Palmer, J. L., Schover, L. R., Yusuf, S. W., Pisters, K., Vassilopoulou‐Sellin, R., DeGracia, B., Willey, J. S., & Bruera, E. (2006) · Cancer · doi:10.1002/cncr.22339 · Cited by 112
Buprenorphine and methadone maintenance treatment of heroin addicts preserves immune function
Sacerdote, P., Franchi, S., Gerra, G., Leccese, V., Panerai, A. E., & Somaini, L. (2008) · Brain Behavior and Immunity · doi:10.1016/j.bbi.2007.12.013 · Cited by 104
Primary care management of opioid use disorders: Abstinence, methadone, or buprenorphine-naloxone?
Srivastava, A., Kahan, M., & Nader, M. (2017) · PubMed · Cited by 104
Quaglio, G., Lugoboni, F., Pattaro, C., Melara, B., Mezzelani, P., & Jarlais, D. C. D. (2008) · Drug and Alcohol Dependence · doi:10.1016/j.drugalcdep.2007.09.025 · Cited by 103
Reddy, R. G., Aung, T., Karavitaki, N., & Wass, J. A. H. (2010) · BMJ · doi:10.1136/bmj.c4462 · Cited by 96
Single opioid administration modifies gonadal steroids in both the CNS and plasma of male rats
Ceccarelli, I., Padova, A. M. D., Fiorenzani, P., Massafra, C., & Aloisi, A. M. (2006) · Neuroscience · doi:10.1016/j.neuroscience.2006.02.044 · Cited by 94
Substance Abuse and Male Hypogonadism
Duca, Y., Aversa, A., Condorelli, R. A., Calogero, A. E., & Vignera, S. L. (2019) · Journal of Clinical Medicine · doi:10.3390/jcm8050732 · Cited by 93
Testosterone deficiency in non-cancer opioid-treated patients
Coluzzi, F., Billeci, D., Maggi, M., & Corona, G. (2018) · Journal of Endocrinological Investigation · doi:10.1007/s40618-018-0964-3 · Cited by 91
Medicinal aspects of opium as described in Avicenna's Canon of Medicine.
Heydari, M., Hashempur, M. H., & Zargaran, A. (2013) · PubMed · Cited by 82
Clark, M. J., Schopp, L. H., Mazurek, M. O., Zaniletti, I., Lammy, A. B., Martin, T., Thomas, F. P., & Acuff, M. E. (2008) · American Journal of Physical Medicine & Rehabilitation · doi:10.1097/phm.0b013e3181837f4f · Cited by 81
Butnariu, M., Quispe, C., Herrera‐Bravo, J., Pentea, M., Sărac, I., Küşümler, A. S., Özçelik, B., Painuli, S., Semwal, P., Imran, M., et al. (2022) · Oxidative Medicine and Cellular Longevity · doi:10.1155/2022/2041769 · Cited by 80
“Remarkably, modern studies have con fi rmed the adverse e ff ect of morphine alkaloids described by Avicenna [151 – 153].”
Opioid-induced endocrinopathies
Fountas, A., Van Uum, S., & Karavitaki, N. (2020) · The Lancet Diabetes & Endocrinology · doi:10.1016/s2213-8587(19)30254-2 · Cited by 77
Regulation of Male Fertility by the Opioid System
Subirán, N., Casis, L., & Irazusta, J. (2011) · Molecular Medicine · doi:10.2119/molmed.2010.00268 · Cited by 76
Yee, A. H. A., Loh, H. S., Hashim, H. M. H., & Ng, C. G. (2013) · The Journal of Sexual Medicine · doi:10.1111/jsm.12352 · Cited by 75
KotliÅ„ska-Lemieszek, A., & Zylicz, Z. (2022) · Drug Design Development and Therapy · doi:10.2147/dddt.s342409 · Cited by 74
Davis, M. P. (2005) · Supportive Care in Cancer · doi:10.1007/s00520-005-0849-9 · Cited by 71
Buprenorphine in the Treatment of Opiate Dependence
Wesson, D. R., & Smith, D. E. (2010) · Journal of Psychoactive Drugs · doi:10.1080/02791072.2010.10400689 · Cited by 67
Opioids in chronic noncancer pain
Manchikanti, L., Benyamin, R. M., Datta, S., Vallejo, R., & Smith, H. S. (2010) · Expert Review of Neurotherapeutics · doi:10.1586/ern.10.37 · Cited by 65
Supraphysiologic-dose anabolic–androgenic steroid use: A risk factor for dementia?
Kaufman, M. J., Kanayama, G., Hudson, J. I., & Pope, H. G. (2019) · Neuroscience & Biobehavioral Reviews · doi:10.1016/j.neubiorev.2019.02.014 · Cited by 64
Prolactin is an important regulator of intestinal calcium transport
Charoenphandhu, N., & Krishnamra, N. (2007) · Canadian Journal of Physiology and Pharmacology · doi:10.1139/y07-041 · Cited by 64
Rubinstein, A. L., Carpenter, D. M., & Minkoff, J. R. (2013) · Clinical Journal of Pain · doi:10.1097/ajp.0b013e31827c7b5d · Cited by 63
Chronic opioid therapy in long-term cancer survivors
Carmona‐Bayonas, A., Jiménez‐Fonseca, P., Castañón, E., Vaswani, A. R., Sánchez-Bayona, R., Custodio, A. B., Calvo-Temprano, D., & Virizuela, J. A. (2016) · Clinical & Translational Oncology · doi:10.1007/s12094-016-1529-6 · Cited by 63
Decreased bone density in men on methadone maintenance therapy
Grey, A., Rix‐Trott, K., Horne, A., Gamble, G., Bolland, M., & Reid, I. R. (2011) · Addiction · doi:10.1111/j.1360-0443.2010.03159.x · Cited by 61
MECHANISMS OF ENDOCRINOLOGY: endocrinology of opioids
Fountas, A., Chai, S. T., Kourkouti, C., & Karavitaki, N. (2018) · European Journal of Endocrinology · doi:10.1530/eje-18-0270 · Cited by 60
Ramdurg, S. I., Ambekar, A., & Lal, R. (2011) · The Journal of Sexual Medicine · doi:10.1111/j.1743-6109.2011.02219.x · Cited by 56
Bone mineral density and its determinants in men with opioid dependence
Gotthardt, F., Huber, C., Thierfelder, C., Grize, L., Kraenzlin, M., Scheidegger, C., & Meier, C. (2017) · Journal of Bone and Mineral Metabolism · doi:10.1007/s00774-015-0732-9 · Cited by 55
“Long-term opioid therapy for either addiction or chronic pain induces hypogonadism [17–21] due to central suppression of hypothalamic secretion of gonadotropin-releasing hormone, decreased secretion of gonadotropin-releasing hormone in the pituitary gland and impaired testicular function [23].”
BackgroundYee, A. H. A., Danaee, M., Loh, H. S., Sulaiman, A. H., & Ng, C. G. (2016) · PLoS ONE · doi:10.1371/journal.pone.0147852 · Cited by 54
“In contrast, other studies have found that erectile dysfunction was equally frequent in the two groups [5,6,16,26].”
ResultBuprenorphine/Naloxone for opioid dependence: clinical practice guideline.
Handford, C. D., Kahan, M., Srivastava, A., Cirone, S., & Palda, V. A. (2011) · Cited by 51
Foster, B., Twycross, R., Mihalyo, M., & Wilcock, A. (2013) · Journal of Pain and Symptom Management · doi:10.1016/j.jpainsymman.2013.03.001 · Cited by 49
Rubinstein, A. L., & Carpenter, D. M. (2016) · Pain Medicine · doi:10.1093/pm/pnw182 · Cited by 48
Farag, A. G. A., Basha, M. A., Amin, S. A., Elnaidany, N. F., Elhelbawy, N. G., Mostafa, M., Khodier, S. A., Ibrahem, R. A. L., & Mahfouz, R. Z. (2018) · Andrologia · doi:10.1111/and.13026 · Cited by 48
“Moreover, level of serum FSH and LH, as part of opioid effect on gonadotropinreleasing hormone (GnRH), get affected by hyperprolactinaemia (Bliesener et al., 2005).”
BackgroundDrugs that cause sexual dysfunction.
Smith, S. M. (1983) · PubMed · Cited by 48
Pharmacotherapy of Opioid Addiction: “Putting a Real Face on a False Demon”
Salsitz, E. A., & Wiegand, T. J. (2015) · Journal of Medical Toxicology · doi:10.1007/s13181-015-0517-5 · Cited by 46
Risk Factors of Erectile Dysfunction in Patients Receiving Methadone Maintenance Therapy
Jaafar, N. R. N., Mislan, N., Aziz, S. A., Baharudin, A., Ibrahim, N., Midin, M., Das, S., & Sidi, H. (2013) · The Journal of Sexual Medicine · doi:10.1111/jsm.12105 · Cited by 44
Sexual Dysfunction in Men Seeking Treatment for Opioid Dependence: A Study from India
Kandappan, V., Mattoo, S. K., & Grover, S. (2014) · The Journal of Sexual Medicine · doi:10.1111/jsm.12588 · Cited by 42
Urological complications of illicit drug use
Skeldon, S., & Goldenberg, S. L. (2014) · Nature Reviews Urology · doi:10.1038/nrurol.2014.22 · Cited by 42
Pain Medications and Male Reproduction
Drobnis, E. Z., & Nangia, A. K. (2017) · Advances in experimental medicine and biology · doi:10.1007/978-3-319-69535-8_6 · Cited by 42
Drugs that cause sexual dysfunction
Smith, S. M. (2007) · Psychiatry · doi:10.1016/j.mppsy.2006.12.004 · Cited by 42
New perspectives in functional hypogonadotropic hypogonadism: beyond late onset hypogonadism
Spaziani, M., Carlomagno, F., Tarantino, C., Angelini, F., Vincenzi, L., & Gianfrilli, D. (2023) · Frontiers in Endocrinology · doi:10.3389/fendo.2023.1184530 · Cited by 41
“The prevalence of male hypogonadism is estimated between 19 and 86% (72), and is influenced by treatment duration, dosage and specific opioid medication (73, 74).”
BackgroundBlanco-Gandía, M. C., & Rodríguez‐Arias, M. (2018) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2018.08.007 · Cited by 41
Opioid‐induced hypogonadism: Pathophysiology, clinical and therapeutics review
Antony, T., Alzaharani, S. Y., & El-Ghaiesh, S. H. (2019) · Clinical and Experimental Pharmacology and Physiology · doi:10.1111/1440-1681.13246 · Cited by 40
Yee, A., Loh, H. S., Hashim, H. M. H. H., & Ng, C. (2014) · International journal of impotence research · doi:10.1038/ijir.2014.18 · Cited by 38
Zhang, M., Zhang, H., Shi, C. X., McGoogan, J. M., Zhang, B., LingLong, Z., Zhang, M., Rou, K., & Wu, Z. (2014) · PLoS ONE · doi:10.1371/journal.pone.0088289 · Cited by 38
Opioids and the Hypothalamic-Pituitary-Gonadal (HPG) Axis
Wehbeh, L., & Dobs, A. S. (2020) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/clinem/dgaa417 · Cited by 38
Nna, V. U., & Osim, E. E. (2016) · Andrologia · doi:10.1111/and.12669 · Cited by 36
Erectile Dysfunction in Opioid Users: Lack of Association with Serum Testosterone
Cioe, P. A., Friedmann, P. D., & Stein, M. D. (2010) · Journal of Addictive Diseases · doi:10.1080/10550887.2010.509279 · Cited by 35
Azari, O., Emadi, L., Kheirandish, R., Bafti, H. S., Nejad, M. R. E., & Faroghi, F. (2014) · DOAJ (DOAJ: Directory of Open Access Journals) · Cited by 35
Opioids Increase Sexual Dysfunction in Patients with Non-Cancer Pain
Ajo, R., Segura, A., Inda, M., Planelles, B., Martínez, L. L., Ferrández, G., Sánchez, A., Margarit, C., & Peiró, A. M. (2016) · The Journal of Sexual Medicine · doi:10.1016/j.jsxm.2016.07.003 · Cited by 35
Demarest, S. P., Gill, R. S., & Adler, R. A. (2014) · Endocrine Practice · doi:10.4158/ep14339.ra · Cited by 35
Ruggiero, A., Coccia, P., Arena, R., Maurizi, P., Battista, A., Ridola, V., Attinà, G., & Riccardi, R. (2012) · Pediatric Blood & Cancer · doi:10.1002/pbc.24332 · Cited by 33
“Moreover, this opioid has no negative effects on the immune system [5–7] or on the hypothalamic–pituitary–gonadal axis [8,9] and its pharmacokinetic properties, such as fecal elimination [10], allow its use also in patients with renal impairment [11].”
BackgroundHeidari, Z., Mahmoudzadeh‐Sagheb, H., & Kohan, F. (2012) · international journal high risk behaviors & addiction · doi:10.5812/ijhrba.4119 · Cited by 32
Leri, F., Sorge, R. E., Cummins, E., Woehrling, D., Pfaus, J. G., & Stewart, J. (2007) · Neuropsychopharmacology · doi:10.1038/sj.npp.1301357 · Cited by 31
Jasuja, G. K., Ameli, O., Reisman, J. I., Rose, A. J., Miller, D. R., Berlowitz, D. R., & Bhasin, S. (2019) · JAMA Network Open · doi:10.1001/jamanetworkopen.2019.17141 · Cited by 30
Smith, J. B., Rosen, J. H., & Colbert, A. (2017) · Sexual Medicine Reviews · doi:10.1016/j.sxmr.2017.08.007 · Cited by 29
“This is theorized to be due to buprenorphine’s unique binding profile, with only partial m-opioid agonist and k-opioid antagonist properties counteracting the typical gonadal axis suppression of a full m-opioid agonist.(15)”
BackgroundD epression in male patients on methadone maintenance therapy
Baharudin, A., Mislan, N., Ibrahim, N., Sidi, H., & Jaafar, N. R. N. (2013) · Asia-Pacific Psychiatry · doi:10.1111/appy.12069 · Cited by 29
“Contrary to Bliesener et al. (2005), who used a two-question self-rating scale for sexual function, depression as measured by BDI was not associated with erectile dysfunction in neither methadone nor buprenorphine groups.”
MethodYee, A. H. A., Loh, H. S., Danaee, M., Riahi, S., Ng, C. G., & Sulaiman, A. H. (2017) · The Journal of Sexual Medicine · doi:10.1016/j.jsxm.2017.12.004 · Cited by 28
Opioids and pituitary function: expert opinion
Gadelha, M. R., Karavitaki, N., Fudin, J., Bettinger, J. J., Raff, H., & Ben-Shlomo, A. (2022) · Pituitary · doi:10.1007/s11102-021-01202-y · Cited by 27
“Counter-intuitively, buprenorphine, is in fact less frequently associated with hypogonadism or sexual dysfunction compared with other opioid agonists, such as methadone [45, 46].”
BackgroundLugoboni, F., Zamboni, L., Federico, A., Tamburin, S., & (GICS), F. T. G. I. D. C. S. (2017) · PLoS ONE · doi:10.1371/journal.pone.0188994 · Cited by 27
Wisniewski, A. B., Brown, T. T., John, M., Frankowicz, J. K., Cofranceso, J., Golub, E. T., Ricketts, E. P., & Dobs, A. S. (2007) · Gender Medicine · doi:10.1016/s1550-8579(07)80007-6 · Cited by 27
What Parenteral Opioids to Use in Face of Shortages of Morphine, Hydromorphone, and Fentanyl
Davis, M. P., McPherson, M. L., Mehta, Z. Y., Behm, B., & Fernandez, C. (2018) · American Journal of Hospice and Palliative Medicine® · doi:10.1177/1049909118771374 · Cited by 26
Seeber, B., Böttcher, B., D’Costa, E., & Wildt, L. (2019) · Vitamins and hormones · doi:10.1016/bs.vh.2019.07.001 · Cited by 26
Erectile dysfunction in patients with chronic viral hepatitis: a systematic review of the literature
Fusco, F., d’Anzeo, G., Rossi, A., Sciorio, C., Buonomo, A. R., Bianca, R. D. D. V., Borgia, G., Mirone, V. G., & Gentile, I. (2013) · Expert Opinion on Pharmacotherapy · doi:10.1517/14656566.2013.850073 · Cited by 25
“Furthermore, even if the relationship between sexual dysfunction and the use of some drugs commonly used by patients with hepatic diseases, such as opioids or antidepressants, is described [40-42], no data on the possible relationship between ED and the use of these compounds were found in the available literature, hi…”
BackgroundGhosh, A., Kathiravan, S., Sharma, K., & Mattoo, S. K. (2021) · The Journal of Sexual Medicine · doi:10.1016/j.jsxm.2021.11.018 · Cited by 25
Effects of curcumin on sperm parameters abnormalities induced by morphine in rat
Roshankhah, S., Salahshoor, M. R., Aryanfar, S., Jalili, F., Sohrabil, M., & Jalili, C. (2017) · Journal of Medical and Biomedical Sciences · doi:10.4314/jmbs.v6i2.1 · Cited by 25
WINSTOCK, A. R., Lea, T., & Sheridan, J. L. (2008) · Drug and Alcohol Review · doi:10.1080/09595230802093745 · Cited by 25
“While these figures are broadly similar to those reported in the current study, they are considerably lower than the levels in excess of 70% reported among methadone and buprenorphine patients in a study of male sexual dysfunction [27].”
ResultThe effects of opioids on the endocrine system: an overview
Ali, K., Raphael, J. H., Khan, S., Labib, M. H., & Duarte, R. V. (2016) · Postgraduate Medical Journal · doi:10.1136/postgradmedj-2016-134299 · Cited by 24
“studies have suggested that buprenorphine has one of the least inhibitory effects on sex hormones due to its nature as a partial ʮ agonist.[17,18]”
BackgroundSeriwatanachai, D., Krishnamra, N., & Charoenphandhu, N. (2012) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2012.02.123 · Cited by 24
Medical therapies causing iatrogenic male infertility
Velez, D., & Ohlander, S. J. (2021) · Fertility and Sterility · doi:10.1016/j.fertnstert.2021.07.1202 · Cited by 23
Dergham, L. (2009) · Elsevier eBooks · doi:10.1016/b978-0-323-05674-8.50020-7 · Cited by 22
A systematic review of opioid effects on the hypogonadal axis of cancer patients
McWilliams, K., Simmons, C., Laird, B. J., & Fallon, M. T. (2014) · Supportive Care in Cancer · doi:10.1007/s00520-014-2195-2 · Cited by 20
“Buprenorphine is preferable to methadone in terms of improved testosterone levels and sexual function [21, 22].”
BackgroundSalah, S., Wagih, M., Zaki, A. R., Fathy, W., & Eid, A. (2019) · Middle East Fertility Society Journal · doi:10.1186/s43043-019-0003-0 · Cited by 20
Bishop, B., Gilmour, J. A., & Deering, D. (2018) · International Journal of Mental Health Nursing · doi:10.1111/inm.12523 · Cited by 20
Beeinträchtigung der Sexualfunktion durch Psychopharmaka und psychotrope Substanzen
Cohen, S., Kühn, K. ‐., Sträter, B., Scherbaum, N., & Weig, W. (2010) · Der Nervenarzt · doi:10.1007/s00115-010-3074-9 · Cited by 19
Metadata
- Authors
- Bliesener, N., Albrecht, S., Schwager, A., Weckbecker, K., Lichtermann, D., & Klingmüller, D.
- Affiliations
- University of Bonn (DE)
- ORCID
- Weckbecker, Klaus
- Venue
- The Journal of Clinical Endocrinology & Metabolism
- Publisher
- The Endocrine Society
- Published
- 2005-01
- Volume
- 90
- Issue
- 1
- Pages
- 203-206
- ISSN
- 0021-972X (ISSN-L)
- 1945-7197
- OpenAlex
- W2164669880
- Semantic Scholar
- 6b922b7d804a6488ee6c5032a29f420570446a72
- Cited by
- 236
- References
- 14
- Citations by year
- 2026: 3 · 2025: 9 · 2024: 6 · 2023: 5 · 2022: 15 · 2021: 13 · 2020: 9 · 2019: 16 · 2018: 15 · 2017: 11 · 2016: 15 · 2015: 8 · 2014: 14 · 2013: 16 · 2012: 16
- FWCI
- 6.42
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- The Journal of Clinical Endocrinology & Metabolism (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Hormonal and reproductive studies
- Health Sciences › Medicine › Public Health, Environmental and Occupational Health › Opioid Use Disorder Treatment
- Health Sciences › Medicine › Reproductive Medicine › Hypothalamic control of reproductive hormones
- Keywords
- buprenorphine, methadone, opioid use disorder, testosterone, sexual dysfunction, hypogonadism, heroin addiction, gonadal axis, depression, gonadotropins, prolactin, estradiol, sex hormone-binding globulin
- MeSH terms
- Adult, Buprenorphine, Estradiol, Humans, Male, Methadone, Opioid-Related Disorders, Sexual Behavior, Sex Hormone-Binding Globulin, Testosterone
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.